Diabetes has been reported to affect the microvasculature and lead to cerebral small vessel disease (SVD). Past studies using arterial spin labeling (ASL) at single post-labeling delay reported reduced cerebral blood flow (CBF) in patients with type 2 diabetes. The purpose of this study was to characterize cerebral hemodynamic changes of type 2 diabetes using a multi-inversion-time 3D GRASE pulsed ASL (PASL) sequence to simultaneously measure CBF and bolus arrival time (BAT). Thirty-six patients with type 2 diabetes (43–71 years, 17 male) and 36 gender- and age-matched control subjects underwent MRI scans at 3 T. Mean CBF/BAT values were computed for gray and white matter (GM and WM) of each subject, while a voxel-wise analysis was performed for comparison of regional CBF and BAT between the two groups. In addition, white matter hyperintensities (WMHs) were detected by a double inversion recovery (DIR) sequence with relatively high sensitivity and spatial resolution. Mean CBF of the WM, but not GM, of the diabetes group was significantly lower than that of the control group \((p < 0.0001)\). Regional CBF decreases were detected in the left middle occipital gyrus \((p = 0.0075)\), but failed to reach significance after correction of partial volume effects. BAT increases were observed in the right calcarine fissure \((p < 0.0001)\), left middle occipital gyrus \((p < 0.0001)\), and right middle occipital gyrus \((p = 0.0011)\). Within the group of diabetic patients, BAT in the right middle occipital gyrus was positively correlated with the disease duration \((r = 0.501, p = 0.002)\), BAT in the left middle occipital gyrus was negatively correlated with the binocular visual acuity \((r = -0.408, p = 0.014)\). Diabetic patients also had more WMHs than the control group \((p = 0.0039)\). Significant differences in CBF, BAT, and more WMHs were observed in patients with diabetes, which may be related to impaired vision and risk of SVD of type 2 diabetes.

Keywords: arterial spin labeling, cerebral blood flow, bolus arrival time, type 2 diabetes, white matter hyperintensity, double inversion recovery
INTRODUCTION

As the most common metabolic disorder in humans, type 2 diabetes is characterized by insulin resistance and relative insulin deficiency. Patients with type 2 diabetes are prone to developing long-term complications affecting the eyes, kidneys, heart, blood vessels, and nerves. These complications can affect the life quality and increase the mortality of patients with type 2 diabetes (1). Diabetes retinopathy is a common complication of diabetes with a prevalence of 24.5% in those with known type 2 diabetes (2, 3). Even with the availability of effective treatment, it remains one of the leading causes of visual loss (4–6).

Type 2 diabetes can affect the central nervous system (7), resulting in cognitive decline, metabolic, and vascular changes (8) affecting both the micro and macro vasculature (9). It has been hypothesized that hypoperfusion may underlie impaired cognitive function associated with type 2 diabetes. Reduced cerebral blood flow (CBF) has been reported using single-photon emission computed tomography (SPECT) (10) and arterial spin labeling (ASL) (11, 12). In brain MRI, patients with type 2 diabetes exhibit more cortical and subcortical atrophy (13) and more deep white matter (WM) lesions (14, 15) than control subjects. In addition, impaired blood–brain barrier (BBB) function has been implicated in cerebral effects of type 2 diabetes (16).

Arterial spin labeling is a non-invasive technique, which labels the protons contained in the arterial blood water by exciting them through radiofrequency pulses, without the need of exogenously administered contrast media (17, 18). This is especially beneficial for patients with type 2 diabetes, who are frequently ineligible for undergoing infusion of gadolinium-based contrast agents, due to the chronic diabetic complications affecting kidneys (chronic renal failure). However, to date, there are only a limited number of ASL studies having studied CBF changes in patients with diabetes. A recent longitudinal study using pseudo-continuous ASL found decreased global CBF as well as regional CBF in the resting-state default mode, visual, and cerebellum networks in patients with type 2 diabetes. Greater decrease in longitudinal CBF values at these regions over a 2-year span was associated with worse cognitive functions, and higher baseline insulin resistance (12).

As another hemodynamic parameter, bolus arrival time (BAT) also provides clinically relevant information regarding the status of cerebrovasculature but has not been explored in type 2 diabetes. In this study, we applied a multi-inversion-time (mTI) 3D GRASE pulsed ASL (PASL) sequence to simultaneously measure CBF and BAT in a cohort of subjects with type 2 diabetes, and compared the results with those of matched control subjects. This mTI 3D GRASE PASL protocol can not only detect both CBF and BAT defects in patients with diabetes but also make more accurate quantification of CBF by including BAT measurement. Based on existing literature, we hypothesize that there are decreased CBF and/or prolonged BAT affecting the whole brain (e.g., the WM) and specific cortical regions (e.g., the visual cortex) that are associated with clinical characterization and/or behavioral performance in subjects with type 2 diabetes.

White matter lesions such as white matter hyperintensities (WMHs) are commonly observed in cerebral small vessel disease (SVD) secondary to diabetes (19, 20). In the present study, a 3D double inversion recovery sequence (3D-DIR) was applied for the detection of WMHs by simultaneously suppressing the signal of cerebrospinal fluid and WM (21). This double inversion recovery (DIR) sequence has been shown to be able to accurately delineate the location and the number of WM lesions in multiple sclerosis (22), and hippocampal pathology (23). The high sensitivity and small slice thickness of 3D-DIR make it suitable for imaging WMHs in type 2 diabetes. We hypothesize that there are greater WMHs in subjects with type 2 diabetes compared to controls that are associated with clinical characterization and/or behavioral performance.

MATERIALS AND METHODS

Subjects

The study was approved by the institutional ethical committee. Informed consent was obtained from all volunteers and patients after the nature of the study had been fully explained to them. Forty-one patients with type 2 diabetes and 41 gender- and age-matched control subjects participated in this study. Between September 2014 and November 2016, patients with type 2 diabetes were recruited in the outpatient department of Shandong Provincial Hospital and control participants were recruited from the spouses or acquaintances of the patients.

For inclusion, type 2 diabetic patients (diagnosed by oral glucose tolerance test) had to be 40–80 years of age, have a disease duration of at least 1 year, and be functionally independent. Exclusion criteria for all participants included a psychiatric or neurological disorder that could influence cognitive functioning, history of alcohol or substance abuse, or history of dementia. All participants did not have a history of stroke and no large confluent WMHs (>20 mm) was found in the DIR image as this lesion may affect the perfusion result. Only small WMHs (≤20 mm) were allowed, which are defined as small lesions located in the WM with the characteristics of hyperintensity on FLAIR, without cavitation (24). Lesions in the subcortical gray matter (GM) or brainstem were not included as WMHs. Participants whose MRI quality was poor due to patients’ movement were excluded from further analyses (n = 5), resulting in a total of 72 participants (36 patients with type 2 diabetes: age 43–71 years old, 17 male; and 36 controls: age 42–76, 14 male). For control participants, exclusion criteria additionally included fasting blood glucose ≥7.0 mmol/L.

The demographic and clinical information about the presence of vascular risk factors was assessed by means of a standardized interview and by physical and laboratory examinations. Blood pressure was measured at nine fixed time points during the day with an automatic blood pressure device. Hypertension was defined as a mean systolic blood pressure above 160 mmHg, a mean diastolic pressure above 95 mmHg, or the use of antihypertensive medication.

MR Imaging

All data were collected on an MAGNETOM Skyra 3 T MR scanner (Siemens, Erlangen, Germany) using a 20-channel head-neck coil. The MRI exam consisted of multi-T1 ASL, T1 MPRAGE, and 3D fast spin-echo double inversion recovery
Neurobehavioral and Binocular Visual Acuity Test

The Montreal Cognitive Assessment (MOCA) was performed on all participants, which has been shown to be a better screening tool for mild cognitive impairment (MCI) in type 2 diabetes population. Compared to Standardized Mini-Mental Status Exam, MOCA has a better sensitivity in diagnosing MCI (25). Binocular visual acuity was measured by standard logarithmic visual acuity chart through bare eye sight.

Data Processing

The model of Buxton et al. (26) was fitted with a nonlinear fitting algorithm (vendor software) to obtain quantitative CBF and BAT maps. The model function used the following parameters: \( \lambda = 0.9, \) T1 of arterial blood = 1,650 ms, T1 of brain tissue = 1,330 ms, and bolus length = 700 ms. CBF and BAT maps were co-registered to the structural MRI, and then normalized to the Montreal Neurological Institute (MNI) space and spatially smoothed with a 6 mm FWHM kernel, using Statistical Parametric Mapping 8.1

First of all, the structural MRI was segmented into GM and WM. The masks of the GM and WM were determined by the threshold of greater than 0.6 for GM and 0.8 for WM on tissue segmentation results using SPM8. The whole brain mask was determined by combining those of the GM and WM. Mean CBF and BAT values were extracted from the GM, WM and whole brain masks, respectively, and compared between the diabetes group and the control group using two-sample \( t \)-test.

A voxel-based analysis was then applied to compare regional CBF and BAT differences between diabetes and control groups, using a two-sample two-sided \( t \)-test. The threshold was set to the false discovery rate corrected \( p < 0.05 \) with a cluster size of 50 voxels to localize those brain regions with significant differences between the two groups.

Corrections of potential partial volume effects (PVE) on regional CBF differences were performed according to the methods described in Du et al. (27). The GM and WM probability maps obtained through voxel-based morphometry (28) of SPM8 were down-sampled to the spatial resolution of perfusion MRI. We assumed that perfusion of WM is 40% of that of GM based on previous PET study (29). To account for PVE, ASL-CBF were corrected according to the following equation: \( I_{\text{corr}} = I_{\text{uncorr}}/(\text{GM} + 0.4 \times \text{WM}) \), where \( I_{\text{corr}} \) and \( I_{\text{uncorr}} \) are the corrected and uncorrected intensities, and GM and WM are the tissue probabilities, respectively.

White matter hyperintensities were detected and quantified on 3D DIR images according to consensus criteria by Wardlaw et al. (30). Participants with large confluent WMHs were excluded (＞20 mm) because they may affect CBF. Only the number of WMHs on the SPACE-DIR images was assessed by two neuroradiologists independently who were blinded to the origin of data and the mean value was used for analysis. Each neuro-radiologist counted the number of WMHs 3 times from axial, coronal, and sagittal views of 3D DIR images, respectively, and the mean number was reported. We defined five levels according to the number of the WMHs: Level 1 (0), Level 2 (1–3), Level 3 (4–10), Level 4 (11–20), Level 5 (≥21). The inter-rater agreement was calculated for grading of WMHs using Cohen’s kappa in SPSS Statistics 17.0 (IBM, Chicago, IL, USA).

Statistical Analysis

Differences in neuropsychological performance and MR variables between patient and control groups were analyzed with multivariable linear regression adjusted for age and sex. Statistical maps were overlaid onto a high-resolution brain template in the standard MNI space using XJVIEW software.2 To investigate the relationship between the abnormal cerebral perfusion patterns (i.e., BAT and CBF) and clinical characteristics, the regional values of BAT and CBF in the identified brain areas were correlated with the illness duration using Pearson’s correlation. The statistical analyses were performed using GraphPad Prism 5 software (GraphPad Software, Inc.).

To determine whether CBF, BAT, and the number of WMHs in diabetic patients was related to the disease duration and binocular visual acuity, we correlated mean CBF and BAT in the clusters displaying significant group differences with the disease duration and binocular visual acuity across diabetic subjects. Pearson correlation was also performed between CBF in the significant clusters and MOCA scores. The Kolmogorov–Smirnov and Shapiro–Wilk tests were used to test the normal distribution of variables, and Spearman correlation was applied if the data did not follow normal distribution.

RESULTS

Participants’ Characteristics

Table 1 shows the demographic and clinical information of diabetes and control groups, respectively. The two groups were well balanced in terms of age, sex, and level of education. The diabetic subjects were significantly heavier than controls (\( p = 0.035 \), with
a higher BMI \( (p = 0.091) \). There were no significant differences in terms of comorbid conditions (e.g., hypertension or hyperlipidemia) between the two groups.

**CBF and BAT Changes of the Diabetes Group**

The mean global CBF of the diabetes and control group was \( 47.90 \pm 7.05 \) and \( 47.29 \pm 6.40 \) ml/100 g/min, respectively. The mean global BAT of the diabetes and control group was \( 1.009.0 \pm 52.3 \) and \( 988.1 \pm 54.4 \) ms, respectively. No significant differences were found between the two groups (Figure 1B) except that the CBF of the WM of the diabetes group (\( 30.48 \pm 3.99 \) ml/100 g/min) was significantly lower than that of the control group (\( 35.82 \pm 3.86 \) ml/100 g/min) \( (p < 0.0001) \) (Figure 1A).

Before the PVE correction, significant CBF decreases were detected in the left middle occipital gyrus \( (p = 0.0075) \). After the PVE correction, no significant CBF changes were detected between the diabetes and control group. BAT increases were observed in the right calcarine fissure and surrounding cortex \( (p < 0.0001) \), two clusters in left middle occipital gyrus \( (p < 0.0001) \) and right middle occipital gyrus \( (p = 0.0011) \) (Figure 2; Table 2).

**WMHs of the Two Groups**

The agreement between the two raters was excellent \( (Kappa = 0.924) \) (Figure 3). More WMHs were detected in the diabetic group \( (p = 0.0015) \). The number of WMHs is summarized in Table 3.

**Correlation Analyses**

Within the group of type 2 diabetic patients, the BAT in the right middle occipital gyrus was significantly positively correlated with the disease duration \( (r = 0.501, p = 0.002) \) (Figure 4A); the BAT in the left middle occipital gyrus was significantly negatively correlated with the binocular visual acuity \( (r = -0.406, p = 0.014) \) (Figure 4B). No significant correlation was noted between the CBF in these brain areas, the number of WMHs and illness duration or the age at onset or MOCA scores.

**DISCUSSION**

**Hemodynamic Changes Associated with Type 2 Diabetes**

In this study, we investigated the cerebral hemodynamic and WM changes of type 2 diabetes manifested in CBF, BAT, and WMH by Multi-TI ASL and DIR sequences. We found regional CBF and BAT changes in specific areas of the brain that are correlated with disease duration and binocular visual acuity. However, the mean CBF and BAT in the GM and whole brain did not show significant differences between patient and control groups, similar to previous studies (31, 32). Only the mean CBF of the deep WM showed a significant decrease in patients with type 2 diabetes.

Our results suggest that the cortical GM may be sufficiently perfused in patients with type 2 diabetes, probably due to its

---

**TABLE 1 | Patient characteristics.**

| Participant characteristics | Type 2 diabetes patients | Control subjects | P value |
|----------------------------|--------------------------|------------------|---------|
| Sex (male/female)          | 17/19                    | 14/22            | 0.482   |
| Age (years)                | 57.61 ± 6.21             | 56.19 ± 6.84     | 0.361   |
| Race                       | Asian                    | Asian            |         |
| Education (years)          | 9.06 ± 1.52              | 9.81 ± 2.94      | 0.2     |
| Height (m)                 | 1.67 ± 0.08              | 1.65 ± 0.10      | 0.444   |
| Weight (kg)                | 72.38 ± 9.48             | 66.58 ± 13.05    | 0.005   |
| BMI (kg/m²)                | 25.99 ± 2.88             | 24.44 ± 4.61     | 0.091   |
| Diabetes duration (years)  | 5.43 ± 4.88              | 5.7 ± 0.33       | <0.001*** |
| Recent fasting glucose (mmol/l) | 8.00 ± 1.04         | 5.7 ± 0.33       | <0.001*** |
| Use of insulin (%)         | 18 (50)                  | 13/23            | 0.159   |
| Hypertension (yes/no)      | 20/16                    | 19/27            | 0.159   |
| Hyperlipidemia (yes/no)    | 9/27                     | 8/28             | 0.785   |
| White matter hyperintensities (%) | 29 (81) | 14 (39) | 0.004** |
| Binocular visual acuity    | 4.61 ± 0.25              |                   |         |
| Montreal Cognitive Assessment | 25.69 ± 0.86       | 26.03 ± 0.84     | 0.101   |

*Data shown are means and SD or proportions (%); \( *p < 0.05; **p < 0.005; ***p < 0.001.\)

**FIGURE 1 | Cerebral blood flow (CBF) (A) and bolus arrival time (BAT) (B) of white matter, gray matter and the mean value of the whole brain. D = patients with type 2 diabetes, N = the normal control. ***p < 0.001.**
The difference of bolus arrival time (BAT) between patients with diabetes and the control group as detected by voxel-based analysis. The light blue arrows show three areas with the most significant differences in the BAT maps.

### Table 2

Areas with the most significant differences in the bolus arrival time (BAT) maps as obtained from the voxel-based analysis.

| Brain areas                              | No. of voxels | p-Value     |
|------------------------------------------|---------------|-------------|
| Right calcarine fissure and surrounding cortex (14 – 86 – 2) | 66            | <0.0001     |
| Left middle occipital gyrus (–22 – 84 12/–30 – 60 32) | 252/97        | <0.0001/0.0001 |
| Right middle occipital gyrus (38 – 70 20) | 222           | 0.0011      |

The coordinates refer to the standard Montreal Neurological Institute space.

Bolus arrival time increase in the left middle occipital gyrus, which is primarily associated with visual function (35), was detected in the diabetes group. Additionally, BAT increases were observed in the right calcarine fissure and surrounding cortex, areas also related to visual function (36). These regional BAT changes in visual areas may be linked to the observation that diabetic retinopathy is a very common complication of type 2 diabetes that has associations with the prevalence and severity of cerebral SVD (37). In a previous study of patients with diabetic retinopathy, significantly increased ADC values of the visual center (occipital gyrus) was observed (38). The correlations of prolonged BAT in visual areas with disease duration and binocular visual acuity suggest a potential mechanism of impaired visual function in diabetic patients through delayed arterial blood supply to visual areas. These BAT changes and the decrease of binocular visual acuity may be related to the secondary effect of retinopathy (37, 39). It is worth noting that although visual acuity was not assessed in control subjects in the present study, a previous study has reported normal visual acuity in a comparable group of subjects without diabetes (39) (0.03 ± 0.047 logMAR which can be converted to around 4.9–5.0 in this study).

Bolus arrival time or arterial transit time has been shown to be a valuable marker in cerebrovascular disorders such as common carotid artery occlusion (40). Increased BAT suggests the late arrival of the labeled blood, which may indicate potential increase of vascular resistance and/or redistribution of blood supply. These vascular changes may occur in patients with diabetes due to atherosclerotic plaque progression (41) and in patients with abundant collateral circulation. WM may be especially susceptible to declining perfusion due to its watershed location. In the previous study, hyperglycemia has been shown to lead to a wide variety of vascular abnormalities at the microvascular and macrovascular levels, including abnormal autoregulation (33), remodeling of capillaries (9), and vessel wall (34). All these changes may result in reduced perfusion and increased risk of cerebrovascular diseases.
diabetic retinopathy caused by new vessel formation (42). With BAT, it is possible to measure CBF more accurately and BAT itself provides valuable cerebral hemodynamic information in patients with diabetes.

Regional CBF reduction in the left middle occipital gyrus was observed in the diabetes group compared to controls. However, after correction of PVE, the CBF findings became non-significant, suggesting that this finding may be the result of potentially concomitant atrophy of GM in diabetic patients (43). A very recent study investigated regional CBF changes of patients with type 2 diabetes and found similar CBF reductions of the visual network. They also detected widespread CBF reductions.
in the default mode network and cerebellum (12). However, the enrolled patients were older with longer disease duration compared to those of our study, which may explain different findings of CBF changes between the two studies. In addition, we applied BAT in the present study, which may allow the detection of early hemodynamic changes associated with type 2 diabetes.

In addition, we computed the parenchymal fraction [the ratio (GM + WM volume)/(intracranial volume)], and the mean ratio of the control group (0.7010) was slightly higher than the group of patients with diabetes (0.6903), but no significant difference was found ($p = 0.7995$). After taking this into account, the result of the group differences of global GM and local GM CBF differences did not change. The lack of significant CBF difference after PVE correction may be because the diabetes patients in our study are younger compared to the patient population of a previous study (12) and, therefore, are in a relatively early stage of diabetes.

Past studies have reported controversial findings regarding cerebral hemodynamic changes of diabetes. Some studies denied that CBF is affected by type 2 diabetes (32), nor that cognitive decline is caused by type 2 diabetes (31). Other studies reported regional CBF decrease in patients with diabetes using SPECT (10) and ASL perfusion MRI (11, 12). These different findings in literature may be due to different imaging techniques and post-processing methods employed, as well as different study populations. In previous ASL studies, only a single delay time was applied. A potential strength of our study is that we used a multi-TI ASL perfusion MRI sequence to concurrently measure BAT and CBF in patients with type 2 diabetes. Our results suggest cortical CBF may be compensated in type 2 diabetes through collateral circulation, resulting in prolonged BAT in specific brain regions.

### WM Changes Associated with Type 2 Diabetes

In the present study, 3D SPACE DIR was applied for the detection of WMHs, which has potential advantages (over standard FLAIR) for the detection of infratentorial lesions and lesions with poor contrasts on T2-weighted images (44). Because of the high GM-WM contrast, it is relatively easy to identify the location of lesions (45) with a thin slice thickness of 1.4 mm. The SPACE DIR result shows more WMHs in the diabetes group than the control group. Our findings are consistent with previous studies reporting that significantly more WM lesions were found in patients with type 2 diabetes when compared to control subjects (46).

Past studies reported that CBF decreases in the areas of WMHs (50, 51). One caveat of the present study is that the reported reduced CBF in WM may be due to a larger number of WMHs in the patient group. We attempted to measure and compare the values of CBF within WMHs and in the residual normal appearing white matter. However, we found that the size of most of the WMHs is too small (with diameter $\leq$ 5 mm), thus does not allow accurate measurements of CBF within small ROIs. In addition, the WM mask we used mostly covers deep WM regions while WMHs are spread across WM with few overlaps with the WM mask. Nevertheless, we measured WM CBF by excluding manually drawn ROIs of WMHs within the WM mask, and the reported

#### Table 3

| No. of WMHs | No. of patients with type 2 diabetes | No. of normal control |
|-------------|-------------------------------------|-----------------------|
|             | $N = 36$ (%)                        | $N = 36$ (%)          |
| 0 (Level 1) | 7 (19)                              | 22 (61)               |
| 1–3 (Level 2)| 9 (25)                              | 8 (22)                |
| 4–10 (Level 3)| 8 (22)                             | 1 (3)                 |
| 11–20 (Level 4)| 6 (17)                             | 1 (3)                 |
| $\geq$21 (Level 5)| 6 (17)                           | 4 (11)                |

*Numbers in parentheses represent percentages.*

#### Figure 4

(A) Correlation analysis results between bolus arrival time (BAT) in the right middle occipital gyrus and the disease duration. (B) Correlation analysis results between BAT in the left middle occipital gyrus and the binocular visual acuity.
results of WM CBF reduction in diabetes patients compared to controls remained significant (p < 0.0001).

Limitations of the Study
We note three limitations of our study. First of all, the number of enrolled subjects is relatively small compared to published studies (10, 12, 31, 32). Second, the cognitive assessment (MOCA) is relatively simple and more comprehensive evaluations need to be performed in future studies. Third, we cannot completely rule out effects of concomitant diseases such as hypertension and hyperlipidemia, although there is no significant difference in their presence between the diabetic and control groups. The inclusion of hypertension and hyperlipidemia as covariates in our analyses did not change the reported findings. Nevertheless, a strong interaction of diabetes and hypertension has been reported by a previous study (52). In future studies with large sample size, it is possible to adjust for the effect of hypertension and/or hyperlipidemia (53).

CONCLUSION
In conclusion, using a multi-TI ASL technique, we observed significant differences in WM CBF and regional BAT as well as WMHs in patients with type 2 diabetes compared to normal controls. These hemodynamic differences and WM changes may be related to the complications (especially impaired vision) and risk for developing cerebral SVDs in patients with type 2 diabetes.

ETHICS STATEMENT
The study was approved by the Medical ethics committee of affiliated Provincial Hospital of Shandong University. All patients provided written informed consent.

AUTHOR CONTRIBUTIONS
YS, DJJW, BZ, LY, and KJ designed the study; YS, JW, BW, LY, and KJ performed experiments; YS, JW, BW, LY, and KJ collected and analyzed data; YS, DJJW, LY, and KJ wrote the manuscript; DJ JW, BZ, PJ, TQ, LY, GW, and KJ gave technical support and conceptual advice.

FUNDING
Contract grant sponsor: National Institute of Health (NIH); contract grant number: UH2-NS100614; Contract grant sponsor: Shandong science and technology development plan; contract grant number: 2015GSF118005; Contract grant sponsor: American Heart Association (AHA); contract grant number: 16SDG29630013.

REFERENCES
1. Huang ES, Brown SE, Fwigman BG, Foley EC, Meltzer DO. Patient perceptions of quality of life with diabetes-related complications and treatments. Diabetes Care (2007) 30(10):2478–83. doi:10.2337/dc07-0499
2. Tapp RJ, Shaw JE, Harper CA, De Courten MP, Balkau B, McCarty DJ, et al. The prevalence and extent of factors associated with diabetic retinopathy in the Australian population. Diabetes Care (2003) 26(6):1731–7. doi:10.2337/ diacare.26.6.1731
3. McKay R, McCarty CA, Taylor HR. Diabetic retinopathy in Victoria, Australia: the visual impairment project. Br J Ophthalmol (2000) 84(8):865–70. doi:10.1136/bjo.84.8.865
4. Miller-Meeks M. Diagnosis and management of diabetic retinopathy. Contemp Intern Med (1994) 6(10):13–5, 9–24.
5. Group UPDS. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet (1998) 352(9131):837–53. doi:10.1016/S0140-6736(98)07019-6
6. Group US. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ (1998) 317:703–13. doi:10.1136/bmj.317.7160.703
7. McCall AL. The impact of diabetes on the CNS. Diabetes (1992) 41(5):557–70. doi:10.2337/diabetes.41.5.557
8. Gispert WH, Biessels G-J. Cognition and synaptic plasticity in diabetes mellitus. Trends Neurosci (2000) 23(11):542–9. doi:10.1016/S0166-2236(00)01656-8
9. Fowler MJ. Microvascular and macrovascular complications of diabetes. Clin Diabetes (2008) 26(2):77–82. doi:10.2337/diaclin.26.2.77
10. Nagamachi S, Nishikawa T, Ono S, Ageta M, Matsuo T, Jinnouchi S, et al. Regional cerebral blood flow in diabetic patients: evaluation by N-isopropyl-123I-IMP with SPECT. Nucl Med Commun (1994) 15(6):455–60. doi:10.1097/00006231-199406000-00010
11. Last D, Alsop DC, Abduljalil AM, Marquis RP, De Bazelaira C, Hu K, et al. Global and regional effects of type 2 diabetes on brain tissue volumes and cerebral vasoreactivity. Diabetes Care (2007) 30(5):1193–9. doi:10.2337/ dc06-2052
12. Dai W, Duan W, Alfaro FJ, Gavrieli A, Kourtelidis F, Novak V. The resting perfusion pattern associates with functional decline in type 2 diabetes. Neurobiol Aging (2017) 60:192–202. doi:10.1016/j.neurobiolaging.2017.09.004
13. Chen Z, Li L, Sun J, Ma L. Mapping the brain in type 2 diabetes: voxel-based morphometry using DARTEL. Eur J Radiol (2012) 81(8):1870–6. doi:10.1016/j.ejrad.2011.04.025
14. Reijmer YD, Brundel M, De Bresser J, Kappelle LJ, Leemans A, Biessels GJ, et al. Microstructural white matter abnormalities and cognitive functioning in type 2 diabetes. Diabetes Care (2013) 36(1):137–44. doi:10.2337/dc12-0493
15. Novak V, Last D, Alsop DC, Abduljalil AM, Hu K, Lepoviciski L, et al. Cerebral blood flow velocity and periventricular white matter hyperintensities in type 2 diabetes. Diabetes Care (2006) 29(7):1529–34. doi:10.2337/dci06-0261
16. Mooradian AD. Central nervous system complications of diabetes mellitus – a perspective from the blood-brain barrier. Brain Res Rev (1997) 23(3):210–8. doi:10.1016/S0165-0173(97)00003-9
17. Ferré JC, Bannier E, Raoult H, Mineur G, Carsin-Nicol B, Gauvrit JY. Arterial spin labeling (ASL) perfusion: techniques and clinical use. Diagn Interv Imaging (2013) 94(12):1211–23. doi:10.1002/jmri.23581
18. Detre JA, Rao H, Wang DJ, Chen YF, Wang Z. Applications of arterial spin labeled MRI in the brain. J Magn Reson Imaging (2012) 35(5):1026–37. doi:10.1002/jmri.23581
19. De Bresser J, Diehuus AM, Van Den Berg E, Reijmer YD, Jongen C, Kappelle LJ, et al. Progression of cerebral atrophy and white matter hyperintensities in patients with type 2 diabetes. Diabetes Care (2010) 33(6):1309–14. doi:10.2337/ dc09-1923
20. Brundel M, Kappelle LJ, Biessels GJ. Brain imaging in type 2 diabetes. Eur Neuropsychopharmacol (2014) 24(12):1967–81. doi:10.1016/j.euroneuro.2014.01.023
21. Redpath TW, Smith FW. Imaging gray brain matter with a double-inversion pulse sequence to suppress CSF and white matter signals. Magn Reson Mater Phys Biol Med (1994) 2(3):451–5. doi:10.1007/BF01705296
22. Calabrese M, De Stefano N. Cortical lesion counts by double inversion recovery should be part of the MRI monitoring process for all MS patients: yes. Mult Scler (2014) 20(5):537–8. doi:10.1177/1352458514526084
23. Zhang Q, Li Q, Zhang J, Zhang Y. Double inversion recovery magnetic resonance imaging (MRI) in the preoperative evaluation of hippocampal sclerosis:
correlation with volumetric measurement and proton magnetic resonance spectroscopy (1H MRS). J Comput Assist Tomogr (2011) 35(3):406–10. doi:10.1097/RCT.0b013e318219c2b6
24. Rost NS, Cloonan L, Kanakis AS, Fitzpatrick KM, Azzariti DR, Clarke V, et al. Determinants of white matter hyperintensity burden in patients with Fabry disease. Neurology (2016) 86(20):1880–6. doi:10.1212/WNL.000000000002673
25. Alagiakrishnan K, Zhao N, Mereu L, Senior P, Senthilselvan A. Montreal cognitive assessment is superior to standardized mini-mental status exam in detecting mild cognitive impairment in the middle-aged and elderly patients with type 2 diabetes mellitus. Biomed Res Int (2013) 2013:186106. doi:10.1155/2013/186106
26. Buxton RB, Frank LR, Wong EC, Siewert B, Warach S, Edelman RR. A general kinetic model for quantitative perfusion imaging with arterial spin labeling. Magn Reson Med (1998) 40(3):383–96. doi:10.1002/mrm.1910400308
27. Du A, Jahg H, Hayasaka S, Kramer J, Rosen H, Gorno-Tempini M, et al. Hypoperfusion in frontotemporal dementia and Alzheimer disease by arterial spin labeling MRI. Neurology (2006) 67(7):1215–20. doi:10.1212/01.wnl.0000238163.71349.78
28. Ashburner J, Friston KJ. Voxel-based morphometry – the methods. Neuroimage (2000) 11(6):805–21. doi:10.1006/nimg.2000.0582
29. Leenders K, Perani D, Lammertse A, Heather J, Buckingham P, Jones T, et al. Cerebral blood flow, blood volume and oxygen utilization. Brain (1990) 113(1):27–47. doi:10.1093/brain/113.1.27
30. Wardlaw JM, Smith EE, Biessels GJ, Cordonnier C, Fazekas F, Frayne R, et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurology (2013) 12(8):822–38. doi:10.1016/S1474-4422(13)70124-8
31. Tielhuis AM, Vincken KL, van den Berg E, Hendriks J, Manschot SM, Mali WPTM, et al. Cerebral perfusion in relation to cognitive function and type 2 diabetes. Diabetesologia (2008) 51(7):1321–6. doi:10.1007/s00125-008-1041-9
32. van Laar PJ, van der Graaf Y, Mali WP, van der Grond J, Hendriks J. Effect of cerebrovascular risk factors on regional cerebral blood flow 1. Radiology (2008) 246(1):198–204. doi:10.1148/radiol.2463061912
33. Ciulla TA, Harris A, Latkany P, Piper HC, Arend O, Garzozi H, et al. Ocular perfusion abnormalities in diabetes. Acta Ophthalmologica Scand (2002) 80(5):668–77. doi:10.1034/j.1600-0420.2002.800503.x
34. Harris AK, Hutchinson JR, Sachidanandam K, Johnson MH, Dorrance AM, Stepp DW, et al. Type 2 diabetes causes remodeling of cerebrovasculature via differential regulation of matrix metalloproteinases and collagen synthesis. Diabetes (2005) 54(9):2638–44. doi:10.2337/diabetes.54.9.2638
35. Renier LA, Anurova I, De Velder AG, Carlson S, VanMeter J, Rauschecker JP. Preserved functional specialization for spatial processing in the mid-cerebellar pons of the early blind. Neuron (2010) 68(1):138–48. doi:10.1016/j.neuron.2010.09.021
36. McFadzean R, Brosnaham D, Hadley D, Mutluken E. Representation of the visual field in the occipital striate cortex. Br J Ophthalmol (1994) 78(3):185–90. doi:10.1136/bjo.78.3.185
37. Umemura T, Kawamura T. Retinopathy: a sign of cerebral small vessel disease in diabetes? J Diabetes Investig (2016) 8(4):428–30. doi:10.1111/jdi.12602
38. Wang Z, Lu Z, Li J, Pan C, Jia Z, Chen H, et al. Evaluation of apparent diffusion coefficient measurements of brain injury in type 2 diabetes with retinopathy by diffusion-weighted MRI at 3.0 T. Neuroreport (2017) 28(2):69–74. doi:10.1097/WNR.0000000000001703
39. Samara WA, Shahlaeae A, Adam MK, Khan MA, Chiang A, Maguire JJ, et al. Quantification of diabetic macular ischemia using optical coherence tomography angiography and its relationship with visual acuity. Ophthalmology (2017) 124(2):235–44. doi:10.1016/j.ophtha.2016.10.008
40. Thomas DL, Lythgoe MF, van der Weerd L, Ordidge RJ, Gadian DG. Regional variation of cerebral blood flow and arterial transit time in the normal and hypertrophied rat brain measured using continuous arterial spin labeling MRI. J Cereb Blood Flow Metab (2006) 26(2):274–82. doi:10.1093/jcbfm/9600185
41. Orsaza-G, Plutzky J. The pathologic continuum of diabetic vascular disease. J Am Coll Cardiol (2009) 53(5):535–42. doi:10.1016/j.jacc.2008.09.055
42. Kohnen EM, Patel V, Rassam SM. Role of blood flow and impaired autoregulation in the pathogenesis of diabetic retinopathy. Diabetes (1995) 44(6):603–7. doi:10.2337/diabetes.44.6.603
43. Sabri O, Hellwig D, Schreckenberger M, Schneider R, KAISER H-J, Wagenknecht G, et al. Influence of diabetes mellitus on regional cerebral glucose metabolism and regional cerebral blood flow. Nucl Med Commun (2000) 21(1):19–29. doi:10.1097/00006621-200010000-00005
44. Turetschek K, Wunderbaldinger P, Bankier AA, Zontisch T, Graf O, Mallek R, et al. Double inversion recovery imaging of the brain: initial experience and comparison with fluid attenuated inversion recovery imaging. Magn Reson Imaging (1998) 16(2):127–35. doi:10.1016/S0730-725X(97)00254-3
45. Geurts JJ, Pouwels PJ, Utidehaag BM, Polman CH, Barkhof F, Casteljns JA. Intracortical lesions in multiple sclerosis: improved detection with 3D double inversion-recovery MR imaging 1. Radiology (2005) 236(1):254–60. doi:10.1148/radiol.2361040450
46. van Harten B, Oosterman JM, Potter van Loon B-J, Scheltens P, Weinstein HC. Brain lesions on MRI in elderly patients with type 2 diabetes mellitus. Eur Neurol (2006) 57(7):70–4. doi:10.1159/000098054
47. Mäkimattila S, Malmberg-Cèder K, Häkkinen A-M, Vuori K, Salonen O, Summanen P, et al. Brain metabolic alterations in patients with type 1 diabetes-hyperglycemia-induced injury. J Cereb Blood Flow Metab (2004) 24(12):1393–9. doi:10.1016/j.jcfm.2004.04.004
48. Ueno M, Tomimoto H, Akiyama I, Wakita H, Sakamoto H. Blood-brain barrier disruption in white matter lesions in a rat model of chronic cerebral hypoperfusion. J Cereb Blood Flow Metab (2002) 22(1):97–104. doi:10.1097/00004677-200201000-00012
49. Hatazawa J, Shimosegawa E, Satoh T, Toyoshima H, Okudera T. Subcortical hypoperfusion associated with asymptomatic white matter lesions on magnetic resonance imaging. Stroke (1997) 28(10):1944–7. doi:10.1161/01.STR.28.10.1944
50. Promunjanyakul N, Lahna D, Kaye J, Dodge H, Ertzen-Lyons D, Rooney W, et al. Characterizing the white matter hyperintensity penumbra with cerebral blood flow measures. Neuroimage Clin (2015) 8:822–9. doi:10.1016/j.nicl.2015.04.012
51. Shi Y, Thrippeleton MJ, Makin SD, Marshall I, Geerlings MI, de Craen AJ, et al. Determinants of white matter hyperintensity burden in patients with type 2 diabetes mellitus. J Neurol (2009) 256(5):496–503. doi:10.1007/s00415-008-0910-9
52. Schmidt R, Launer LJ, Nilsson L-G, Pajak A, Sans S, Berger K, et al. Magnetic resonance imaging of the brain in diabetes. Cerebral Effects of Diabetes

**Conflict of Interest Statement:** The authors declare that there is no conflict of interest associated with this manuscript. Publication is approved by all authors and explicitly by the responsible authorities where the work was carried out.

Copyright © 2017 Shen, Zhao, Yan, Jann, Wang, Wang, Pfeuffer, Qian and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.